<DOC>
<DOCNO>EP-0623620</DOCNO> 
<TEXT>
<INVENTION-TITLE>
5-HT3 Pyrrolopyrazine derivatives
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31505	A61P2518	A61K31495	A61P4300	C07D48714	A61P4300	C07D47104	C07D48700	A61P2530	A61P108	C07D47114	A61K31495	A61P2500	C07D47100	A61P2500	A61P2504	C07D48704	A61P2520	A61P2506	A61P2528	A61P100	A61P100	A61K31505	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61P	A61K	A61P	C07D	A61P	C07D	C07D	A61P	A61P	C07D	A61K	A61P	C07D	A61P	A61P	C07D	A61P	A61P	A61P	A61P	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61P25	A61K31	A61P43	C07D487	A61P43	C07D471	C07D487	A61P25	A61P1	C07D471	A61K31	A61P25	C07D471	A61P25	A61P25	C07D487	A61P25	A61P25	A61P25	A61P1	A61P1	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to the compounds of formula (I): 
<
IMAGE
>
  in which A and R1 are as defined in the description. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I):


wherein:

R
1
 represents a group of formula :


wherein R
2
 and R
3
 form, with the nitrogen atom that carries them, a group selected
from :


piperazine,
substituted piperazine,
piperidine,
substituted piperidine,
pyrrolidine,
substituted pyrrolidine,
morpholine,
morpholine substituted by one or more alkyl radicals,
tetrahydropyridine,
thiomorpholine,
azaspirane having from 5 to 12 ring members,
azaspirane having from 5 to 12 ring members, substituted by
one or more alkyl radicals or oxo groups,
mono- or bi-cyclic azacycloalkyl having from 7 to 12 ring members,
optionally including in its skeleton 1 or 2 additional hetero atoms 

selected from oxygen, sulphur and nitrogen,
mono- or bi-cyclic azacycloalkyl having from 7 to 12 ring members,
substituted by one or more alkyl radicals or oxo groups, optionally

including in its skeleton 1 or 2 additional hetero atoms selected from
oxygen, sulphur and nitrogen,
a -NH-(CH
2
)
k
-NH
2
 group wherein k represents an integer equal to 2, 3
or 4, and
a substituted -NH-(CH
2
)
k
-NH
2
 group wherein k is as defined hereinabove,

and A forms, with the 2 carbon atoms to which it is bonded, a ring selected from
benzo, pyrido, pyrazino and pyrimidino; A being unsubstituted or substituted by one or

more radicals selected from:

alkyl,
hydroxy,
alkoxy,
acyl,
alkoxycarbonyl,
halogen,
trifluoromethyl,
-(CH
2
)
m
-phenyl and -O-(CH
2
)
m
-phenyl wherein the phenyl nucleus is itself
unsubstituted or substituted by one or more radicals selected from halogen,

alkyl, alkoxy, hydroxy and trifluoromethyl; and m represents 0 or an integer
from 1 to 4,
-(CH
2
)
m
-Piperazine wherein the piperazine group is itself substituted or
unsubstituted and m is as defined hereinabove,

it being understood that if A forms, with the 2 carbon atoms to which it is bonded, a
benzo ring that is unsubstituted or substituted by trifluoromethyl or fluorine, then R
2

and R
3
 cannot form, with the nitrogen atom that carries them, a piperazine that is
unsubstituted or substituted in the 4-position by a methyl or methylphenyl radical, and

if A forms, with the 2 carbon atoms to which it is bonded, an unsubstituted benzo ring,
then R
2
 and R
3
 cannot form, with the nitrogen atom that carries them, morpholine or a
dimethylaminopropylamino group,
 
it being understood that the term "substituted" used above in respect of the

piperazine, piperidine, pyrrolidine and -NH-(CH
2
)
k
-NH
2
 groups means that those
groups may be substituted by one or more halogen atoms, hydroxy

radicals, oxo radicals, R
4
 radicals or


radicals

R
4
 being selected from:

alkyl,
alkoxy,
alkenyl unsubstituted or substituted by a phenyl radical itself unsubstituted or
substituted by one or more radicals selected from halogen, alkyl, alkoxy,

hydroxy and trifluoromethyl,
-(CH
2
)
n
-R
5
 and


wherein n represents 0 or an integer
from 1 to 5, n' represents an integer from 1 to 5 and wherein R
5

represents a radical selected from phenyl, benzhydryl, thienyl,
pyrrolyl, pyrrolidinyl, furyl, pyrimidinyl, pyridyl, methylenedioxyphenyl,

ethylenedioxyphenyl, naphthyl, quinolyl, isoquinolyl, cycloalkyl
and dicycloalkylmethyl; the term "cycloalkyl" representing a mono- or

bi-cyclic group having from 3 to 12 ring members,

it being possible for those R
5
 radicals themselves to be substituted by
one or more radicals selected from halogen, trifluoromethyl, carboxy,

hydroxy, alkyl and alkoxy,
and -(CH
2
)
n'
-R
6
 wherein n' is as defined hereinabove and R
6
 represents a
group selected from carboxy, alkoxycarbonyl, amino, alkylamino,

dialkylamino, -SO
2
NR
7
R
8
 and -CONR
7
R
8
 wherein R
7
 and R
8
 each
independently of the other represent a hydrogen atom or alkyl,

their optical isomers,

and addition salts thereof with a pharmaceutically acceptable acid or base,
 
it being understood that, unless indicated to the contrary,


the terms "alkyl", "alkoxy" and "acyl" represent linear or branched groups having from
1 to 6 carbon atoms, and
the term "alkenyl" represents an unsaturated linear or branched group having from 2
to 6 carbon atoms.
Compounds of formula (I) according to claim 1 wherein A forms, with the
2 carbon atoms to which it is bonded, a benzo ring,


their optical isomers,
and addition salts thereof with a pharmaceutically acceptable acid or base.
Compounds of formula (I) according to claim 1 wherein A forms, with the
2 carbon atoms to wh
ich it is bonded, a pyrido ring,

their optical isomers,
and addition salts thereof with a pharmaceutically acceptable acid or base.
Compounds of formula (I) according to claim 1 wherein R
2
 and R
3
 form, with
the nitrogen atom that carries them, a piperazine substituted in the 4-position by a

benzyl radical which is itself unsubstituted or substituted,

their optical isomers,
and addition salts thereof with a pharmaceutically acceptable acid or base.
Compound according to claim 1 which is 4-(4-benzylpiperazino)-pyrrolo[1,2-a]quinoxaline

and addition salts thereof with a pharmaceutically acceptable acid.
Compound according to claim 1 which is 4-(4-benzylpiperazino)-7-chloropyrrolo[1,2-a]quinoxaline

and addition salts thereof with a pharmaceutically
acceptable acid. 
Compound according to claim 1 which is 7-chloro-4-[4-(3,4-methylenedioxybenzyl)piperazino]-pyrrolo[1,2-a]
quinoxaline
and addition salts thereof with a

pharmaceutically acceptable acid.
Compound according to claim 1 which is 6-(4-benzylpiperazino)-pyrido[3,2-e]pyrrolo[1,2-a]
pyrazine
and addition salts thereof with a pharmaceutically acceptable

acid.
Compound according to claim 1 which is 6-(4-allylpiperazino)-pyrido[3,2-e]pyrrolo[1,2-a]
pyrazine
and addition salts thereof with a pharmaceutically acceptable

acid.
Compound according to claim 1 which is 6-[4-(3,4-methylenedioxybenzyl)-piperazino]-pyrido[3,2-e]
pyrrolo[1,2-a]pyrazine

and addition salts thereof with a
pharmaceutically acceptable acid.
Compound according to claim 1 which is 6-(piperazino)-pyrido[3,2-e]pyrrolo[1,2-a]
pyrazine
and addition salts thereof with a pharmaceutically acceptable

acid.
Compound according to claim 1 which is 6-(4-methylpiperazino)-pyrido[3,2-e]pyrrolo[1,2-a]
pyrazine
and addition salts thereof with a pharmaceutically acceptable

acid.
Compound according to claim 1 which is 4-[4-(4-fluorobenzyl)piperazino]-7-methoxy-pyrrolo[1,2-a]
quinoxaline
and addition salts thereof with a pharmaceutically

acceptable acid.
Process for the preparation of compounds of formula (I) according to claim 1,
characterised in that either:


a compound of formula (II) 


wherein A is as defined in claim 1, is refluxed, in the presence of phosgene, or
a compound of formula (II/1)


wherein A is as defined in claim 1, is heated, in the presence or absence of a solvent,

to obtain a compound of formula (I/a):


wherein A is as defined hereinabove

which compound of formula (I/a) is subjected to a halogenation agent to obtain a
compound of formula (I/b) :


 
wherein A is as defined hereinabove,

which is then reacted with an amine of formula (III) :


wherein R
2
 and R
3
 are as defined in claim 1,

to obtain a compound of formula (I) according to claim 1 :


wherein A, R
2
 and R
3
 are as defined hereinabove,

which compounds of formula (I) according to claim 1 can be :

purified in accordance with one or more purification methods selected
from crystallisation, chromatography on a silica column, extraction,

filtration and passage over charcoal and/or resin,
separated, where appropriate, in pure form or in the form of a mixture,
into their possible optical isomers, and/or
converted into salts by a pharmaceutically acceptable acid or base.
Process for the preparation of compounds of formula (I) according to claim 1,
characterised in that :

a compound of formula (II') : 


wherein A is as defined in claim 1,

is reacted with an amine of formula (III) :


wherein R
2
 and R
3
 are as defined in claim 1

to obtain a compound of formula (V) :


wherein A, R
2
 and R
3
 are as defined hereinabove,

which is then cyclised under the action of a halogenation agent and subjected to
alkaline treatment to yield a compound of formula (I) according to claim 1 :


 
wherein A, R
2
 and R
3
 are as defined hereinabove,

which compounds of formula (I) according to claim 1 can be :

purified in accordance with one or more purification methods selected
from crystallisation, chromatography on a silica column, extraction,

filtration and passage over charcoal and/or resin,
separated, where appropriate, in pure form or in the form of a mixture,
into their possible optical isomers, and/or
converted into salts by a pharmaceutically acceptable acid or base.
Pharmaceutical compositions comprising as active ingredient at least one of
the compounds of formula (I) or an addition salt thereof with a pharmaceutically

acceptable acid or base, in combination with one or more pharmaceutically acceptable
excipients or carriers.
Pharmaceutical compositions according to claim 16 for use in the prevention
and treatment of anxiety, depression, stress, psychoses, schizophrenia, disorders of

the central nervous system, migraine, memory disorders, eating disorders, alcoholism
and pain, and in the prevention and treatment of vomiting and gastric emptying

disorders.
</CLAIMS>
</TEXT>
</DOC>
